Sign in
Not yet taking people in NetherlandsPhase 1

Tests an oncolytic adenovirus immunotherapy in adults with recurrent glioblastoma

Tests a virus-based immunotherapy, given repeatedly, in adults with recurrent glioblastoma.

Key facts

Who runs it
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Where
Amsterdam and Rotterdam, NetherlandsSee the 2 sites
Registry title
A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)
Status
Not yet recruiting
Phase
Phase 1
People taking part
18 people, planned
Started
1 Oct 2026
Expected to end
16 Sept 2030
Type of study
Interventional
Record updated
21 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose glioblastoma, a type of brain tumour, has come back. It tests an oncolytic adenovirus immunotherapy given more than once.

Age
18 Years and older
Sex
All sexes can join
Disease stage
Recurrent glioblastoma (the tumour has come back)

Main reasons for not taking part

  • Healthy volunteers cannot join

Where in Netherlands

  • Amsterdam UMC StichtingAmsterdam, NetherlandsNot yet recruiting
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Tests an oncolytic adenovirus immunotherapy in adults with recurrent glioblastomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
21 August 2026